Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;8(2):e002387.
doi: 10.1136/rmdopen-2022-002387.

'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps

Affiliations
Review

'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps

Yvonne Tan et al. RMD Open. 2022 Jul.

Abstract

The European Alliance of Associations for Rheumatology recently defined difficult to treat (D2T) rheumatoid arthritis (RA) and provided points to consider in its management. This review summarises the key concepts of D2T-RA that underpinned this recent guidance. D2T-RA is primarily characterised by failure of at least two different mechanism of action biologic/targeted synthetic disease-modifying antirheumatic drug (DMARDs) with evidence of active/progressive disease. The basis for progressive disease, however, is not limited to clear inflammatory joint pathology, capturing wider contributors to treatment cycling such as comorbidity, obesity and fibromyalgia. This means D2T-RA comprises a heterogeneous population, with a proportion within this exhibiting bona fide treatment-refractory disease. The management points to consider, however, emphasise the importance of checking for the presence of inflammatory pathology before further treatment change. This review suggests additional considerations in the definition of D2T-RA, the potential value in identifying D2T traits and intervening before the development of D2T-RA state and the need for real world evidence of targeted synthetic DMARD in this population to compare to recent trial data. Finally, the review asks whether the presence of D2T-RA implies a failure to treat effectively from the outset, and the need for pharmacological and non-pharmacological management approaches to address the wider D2T-RA population effectively.

Keywords: biological therapy; rheumatoid arthritis; therapeutics.

PubMed Disclaimer

Conflict of interest statement

Competing interests: MHB is supported by the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre and is in receipt of an NIHR Senior Investigator award.

Figures

Figure 1
Figure 1
EULAR definition of difficult-to-treat rheumatoid arthritis (D2T-RA). EULAR, European Alliance of Associations for Rheumatology.
Figure 2
Figure 2
Postulated opportunity for interventions to address difficult to treat traits early to modify a D2T-RA course. RA, rheumatoid arthritis.
Figure 3
Figure 3
D2T (or challenging) traits, development of a D2T course and the presence of refractory RA.
Figure 4
Figure 4
Factors to consider in the definition of difficult to treat rheumatoid arthritis.
Figure 5
Figure 5
The multiple contributors to a difficult to treat rheumatoid arthritis state.

Similar articles

Cited by

References

    1. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79:685–99. 10.1136/annrheumdis-2019-216655 - DOI - PubMed
    1. Nagy G, Roodenrijs NM, Welsing PM, et al. . EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis 2021;80:31–5. 10.1136/annrheumdis-2020-217344 - DOI - PMC - PubMed
    1. Roodenrijs NMT, Welsing PMJ, van der Goes MC, et al. . Healthcare utilization and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study. Rheumatology 2021;60:4681–90. 10.1093/rheumatology/keab078 - DOI - PubMed
    1. Roodenrijs NMT, de Hair MJH, van der Goes MC, et al. . Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Ann Rheum Dis 2018;77:77. 10.1136/annrheumdis-2018-213687 - DOI - PubMed
    1. Kearsley-Fleet L, Davies R, De Cock D, et al. . Biologic refractory disease in rheumatoid arthritis: results from the British Society for rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis 2018;77:1405–12. 10.1136/annrheumdis-2018-213378 - DOI - PMC - PubMed

MeSH terms